Introduction
Oral squamous cell carcinoma (SCC) remains a significant health problem (Parkin et al., 1999) . The 5-year survival rate, at 40%, is among the worst of all sites in the body and has not improved over the past 40 years (Parkin et al., 1999) . Oral epithelial dysplasia often precedes SCC development. Hence, there is both a need for more effective therapies and also the opportunity to recognize premalignant lesions and initiate chemoprevention, ideally targeting specific genes deregulated in oral cancer. Oral SCC development and progression from dysplasia is associated with accumulation of genetic and epigenetic alterations. In particular, deletions of 3p and 9p and activation of telomerase are thought to be among the earlier events, and are followed by amplification of CCND1 and deletions involving 8p, 17p, 13q and 18q. Upregulation of EGFR and inactivation of p53 are also observed frequently (Kim and Califano, 2004) . Specific therapies targeting some of these genes are currently being evaluated in the clinic (Mao et al., 2004) . Nevertheless, other candidate oncogenes and tumor suppressors could be identified by analysis of genes mapping to regions of genomic aberration in oral SCC, but this approach is not straightforward, since these regions often encompass whole chromosome arms, making identification of key genes difficult and requiring extensive evaluation of many genes. Generally, investigations have focused on identification of single driver genes within a region of aberration. For example, CCNL1 and LRP2 were identified in this way as genes overexpressed in oral SCC (Redon et al., 2002; Garnis et al., 2004) .
Although there is some controversy surrounding the functional significance of the many DNA copy number changes seen in tumor genomes, amplifications, defined as regions of focal high-level copy number change (Snijders et al., 2003) , are likely to represent alterations continuously under selection for tumor growth, since studies indicate that the amplified DNA is unstable (Miele et al., 1989; Murnane and Sabatier, 2004; Roth and Andersson, 2004; Shimizu et al., 2005) . On the other hand, there are many other ways to upregulate gene expression in addition to increasing the copy number of the gene . Bearing in mind these observations, we hypothesized that even rarely occurring amplicons would be informative regarding genes important in tumor development, the rationale being that expression of a gene might be altered by copy number in some cases, but more often its expression could be altered by other mechanisms. Furthermore, the pathway in which the gene functions might be altered at a number of points by disrupting upstream or downstream genes by different mechanisms. Therefore, genes mapping in amplicons might help to focus attention on pathways likely to be deregulated in tumors and amplicons, even rare ones, encompassing a limited region of the genome can facilitate identification of candidate pathways because the number of genes in the region is likely to be smaller. This approach takes advantage of the selection by the tumor for amplification of the region to identify candidate pathways that may be deregulated in cancer, rather than focusing on definitive identification of the driver genes for particular amplicons. To apply this logic to oral SCC, we used array CGH to obtain genome-wide information on copy number alterations. We identified regions of recurrent gene amplification and carried out expression analysis of genes mapping within these amplified regions. These analyses found genes involved in integrin signaling, cell survival, and adhesion and migration to be amplified and/or overexpressed. They also identified members of the hedgehog and notch pathways to be amplified and/ or overexpressed. Further analyses revealed deregulated expression of other members of these pathways, which control normal proliferation and differentiation (Ingham and McMahon, 2001; Hansson et al., 2004) . These observations implicate misspecification of cell fate in the development of oral cancer and suggest the possibility of applying new therapeutic approaches targeting members of the hedgehog and notch signaling pathways (Pasca di Magliano and Hebrok, 2003; Watkins and Peacock, 2004) .
Results and discussion
We carried out a genome-wide analysis of copy number aberrations in 89 oral SCC (Figure 1a ) taken from four different sites in the oral cavity (Table 1) . This analysis revealed a number of frequent low-level gains and losses ( Figure 1b ) and 18 regions of recurrent amplification (Table 2) , a number of which contained genes found previously to be amplified and/or overexpressed in oral SCC. Hierarchical clustering of the array CGH data of all 89 tumors revealed two main branches in the dendrogram (Figure 2a) , one of which is significantly enriched with tumors with mutations in TP53 exons 5-8 (Fisher exact test P-value ¼ 0.001). Regardless of position in the dendrogram, low level copy number alterations significantly associated with TP53 mutational status after maxT (Westfall and Young, 1993) correction for multiple testing included À8p, þ distal 8q, À10q, À11q and À18q (Figure 2b ). In addition, we observed that mutation of TP53 was positively correlated with amplification of CCND1 (Fisher exact test Pvalue ¼ 0.009), confirming a previous report (Mineta et al., 1997) and with amplification of EGFR (Fisher exact test P-value ¼ 0.036). 1  2  3  4  5  6  7  8  9  1 0  1 1  1 2  1 3  1 6  15  14  17  20 21  19  18 22 chromosome a b Figure 1 Genome-wide analysis of copy number aberrations in 89 oral SCC. (a) Normalized copy number ratios of genomic DNA from an oral SCC from the buccal mucosa of a male patient compared to normal female reference DNA. Plotted is the normalized log 2 ratio for each clone sorted by chromosome and ordered according to genome position from the p-arm to the q-arm. Multiple lowlevel DNA copy number aberrations are present, including loss of chromosome 3p, 5q, 8p, 18 and 21 and gain of chromosome 7p, 8q, 9q and 20p. This tumor also has an amplification at 11q13 including CCND1. We then focused on the nine amplicons with boundaries spanning less than 3 Mb (Table 2, Figure 3 ). We identified two regions containing genes frequently amplified and/or over-expressed in oral SCC, including EGFR (n ¼ 10 cases) at 7p11.2, and/or two separate, but co-amplified regions at 11q13 encompassing CCND1, FGFR3, FGFR4 and EMS1 in a 1.5 Mb amplicon and PAK1 in a separate 0.9 Mb amplicon (n ¼ 10 cases). The remaining seven amplicons did not contain wellestablished oncogenes in oral SCC. Therefore, to identify the driver genes in these amplicons, we evaluated transcript levels of candidate genes mapping in the minimum amplicon in a set of 24 tumors using the quantitative reverse transcription polymerase chain reaction (RT-PCR) and compared the expression levels to normal samples from the tongue (n ¼ 2) and buccal mucosa (n ¼ 1). These analyses ( . In all cases, we observed increased expression of these genes when they were amplified, but more frequently they were overexpressed without amplification, suggesting that they are likely candidate driver genes for amplification of their respective amplicons. We consider BIRC3 and KIAA0746 less likely to be driver genes, since we observed little upregulation of these genes when amplified. Furthermore, they are expressed in lymphatic tissue and thus, overexpression in tumor samples probably reflects inflammatory infiltrate (Supplementary Table A ). On the other hand, we observed high levels of expression of FJX1 in lymph nodes, but not in a buccal mucosa sample with lymphocytic infiltrate. Since FJX1 was highly upregulated when amplified, we retained FJX1 as a candidate driver gene for amplification at 11p13.
Based on the known functions of the candidate genes, we can propose plausible roles in tumorigenesis, including deregulation of transduction of integrin signaling (TLN1) (Nayal et al., 2004) , opposition to apoptosis (YAP1 and BIRC2), and adhesion and migration (TLN1, LAMA3, MMP7) (Lohi, 2001; Nayal et al., 2004) . However, we were particularly interested in the observed amplification and overexpression of GLI2, JAG1, RBPSUH and FJX1, members of the hedgehog and notch pathways. These ontogenetic networks function in cell fate specification and are widely conserved across phyla. Deregulated hedgehog signaling is a hallmark of basal cell carcinomas of the skin (Ruiz i Altaba et al., 2002) and odontogenic keratocysts in the oral cavity (Ohki et al., 2004) , both of which are phenotypically distinct from SCC. On the other hand, notch signaling promotes differentiation in skin (Lefort and Dotto, 2004 ) and loss of function of notch is permissive for tumor formation in mouse models (Nicolas et al., 2003) . Although two expression array studies found upregulation of some members of the wnt and notch signaling pathways in head and neck SCC (Leethanakul et al., 2000; Ha et al., 2003) , the hedgehog and notch pathways have not been previously characterized in oral squamous cell tumorigenesis. Therefore, we investigated whether expression levels of other members of the hedgehog and notch pathways were altered in oral SCC.
Hedgehog signaling involves secretion of the hedgehog morphogens, Sonic (SHH), Indian (IHH) and Desert (DHH) hedgehog, which interact with Patched (PTCH) to relieve inhibition of Smoothened (SMO), resulting in activation of the transcription factors, GLI1, GLI2 and GLI3 (Ingham and McMahon, 2001; Taipale and Beachy, 2001) . We observed that GLI2 expression was positively correlated with expression of GLI1 Agren et al., 2004) . We observed that SMO was more than twofold downregulated in the majority of tumors (11/23 for which an expression measurement was available). Limited analysis of oral SCC cell lines has shown that SHH is expressed in several and further that the pathway is likely to be active in at least one cell line, since growth can be inhibited by exposure to the Smoothened inhibitor cyclopamine (Nishimaki et al., 2004) . However, we found no expression of SHH, IHH or DHH in normal tissue and only rarely detected expression in tumors (0/23, 0/21 and 1/5 tumors for which an expression measurement was available, respectively), whereas we did observe expression of SHH in the colon carcinoma cell line HCT116 in agreement with a previously published report , indicating that the assay is capable of detecting SHH expression. On the other hand, although we detected expression of HHIP, a negative regulator of hedgehog signaling in normal tissue, we found no expression in the majority of tumors (16/20 for which an expression measurement was available). Taken together, these observations suggest that endogenous ligand activation of hedgehog signaling is not inducing GLI2 upregulation in oral SCC, in contrast to small-cell lung carcinoma and tumors from tissues of endodermal origin, including the esophagus, stomach and pancreas Watkins and Peacock, 2004) . While the mechanism for GLI2 upregulation in oral SCC is not known, possible routes include activation of GLI2 via other pathways, such as fibroblast growth factor (Ruiz i Altaba et al., 2002) or the observed downregulation of HHIP, a negative regulator of hedgehog signaling (Chuang and McMahon, 1999; Chuang et al., 2003) . Notch signaling is initiated by interaction of ligands (e.g. DLL1, JAG1) with membrane-bound notch resulting in cleavage of the notch protein. The released notch intracellular domain enters the nucleus and interacts with the transcription factor, RBPSUH, leading to expression of 'hairy enhancer of split' genes (Lefort and Dotto, 2004; Weng and Aster, 2004) . Although notch signaling promotes differentiation in skin (Lefort and Dotto, 2004) , in oral SCC, we found amplification and overexpression of JAG1 and RBPSUH, two genes central to notch signaling. In addition, we observed amplification of FJX1, the human homologue of four-jointed, which acts in Drosophila as a second signal downstream of notch in leg development (Buckles et al., 2001) and in regulation of polarity in ommatidial development (Zeidler et al., 1999) . The function of FJX1 in humans is currently unknown, but amplification of this gene together with JAG1 and RBPSUH in oral SCC suggests that deregulation of notch signaling is likely contributing to development of these tumors. Therefore, we examined the expression of other notch pathway genes in tumors and found that expression of HES1 increased with increasing expression of JAG1 and DLL1 (Supplementary Table A ), suggesting that notch signaling was active in the tumors. We observed that DLL1 and NOTCH4 were upregulated twofold relative to normal tissue (8/21 and 8/19 tumors, respectively), whereas we found a tendency for NOTCH1, 2 and 3 and HES1 to be expressed at lower levels. Upregulation of NOTCH4 is associated with breast and mammary cancer (Weng and Aster, 2004) . Independent confirmation of our observations is provided by recent expression array studies, which found significant upregulation of JAG1 and NOTCH4 in oral SCC compared to normal tissue (Leethanakul et al., 2000; Ha et al., 2003) . These studies together with the data reported here indicate a role for deregulation of notch signaling in oral cancer.
Skin and oral epithelia are continually renewed and show a developmental gradient from the basal layer to the outermost layer where cells are shed. In the oral cavity, epithelial stem cells located in the deep rete ridges divide rarely to give rise to transit amplifying cells, which are committed to differentiation, but divide a limited number of times prior to withdrawing from the cell cycle (Hume and Potten, 1979) . Oral SCC progenitor cells are likely to be stem cells that have acquired appropriate mutations to allow them to proliferate abnormally and/or to render transit amplifying cells resistant to differentiation. Amplification and/or overexpression of members of the hedgehog and notch pathways in tumors suggest that deregulation of these pathways plays a role in misspecification of oral epithelial cell fates leading to tumor development. Since a number of the involved genes may be expressed in various forms with different growth promoting or repressing functions (Ascano et al., 2003; Aho, 2004) and the outcome of notch signaling is context dependent (Weng and Aster, 2004) , identification of the precise roles of these pathways in oral cancer awaits further characterization of the overexpressed proteins and their pathways.
Materials and methods

Tumor samples
Oral SCC and normal tissue specimens and associated clinical data were obtained through the UCSF Oral Cancer Tissue Bank. Normal cervical lymph nodes were removed as part of the surgical treatment for benign oral disease and were also obtained through the UCSF Oral Cancer Tissue Bank. All tissues were fixed in formalin prior to processing in paraffin. Patient consent was obtained for use of all specimens. Prior to nucleic acid extraction, we stained the first and last sections with hematoxylin and eosin. We examined these sections to confirm the diagnosis of SCC prior to collection of material for nucleic acid extraction and to estimate the normal cell content of the regions selected for dissection, which varied from 60 to 90% epithelial cells. Patient samples and characteristics are provided in Table 1 .
Isolation of DNA
We dissected tumor-rich regions from 15 consecutive 10 mm formalin-fixed paraffin-embedded tissue sections from routine surgical biopsies and tumor resections. We de-paraffinized the sections by using three 10 min incubations with 1 ml xylene on a rocking table. We removed the xylene following centrifugation of the sections and then incubated the sections in 1 ml of absolute ethanol for 15 min at room temperature. After removal of the ethanol, we air-dried the sections and then incubated them overnight in 500 ml digestion buffer (100 mM NaCl, 25 mM EDTA, 10 mM Tris-HCl, 0.5% SDS in H 2 O). We treated the sections with 400-500 mg of Proteinase K each day for three consecutive days at 551C and then extracted DNA using phenol-chloroform-isoamyl alcohol (25 : 24 : 1). We precipitated the DNA with ethanol and ammonium acetate in the presence of 100 mg glycogen and collected the pellet by centrifugation. We dissolved the air-dried pellet in 15 ml H 2 O and determined the DNA concentration by fluorometry.
Array CGH
We carried out array CGH as described previously (Snijders et al., 2003) . Briefly, to label genomic DNA (600 ng), we used random priming to incorporate Cy3-or Cy5 dCTP in a 50 ml reaction. We hybridized labeled test (600 ng) and reference DNAs (300 ng) together with 100 mg human Cot-1 DNA for B48 h at 371C to arrays of 2464 BAC clones each printed in triplicate (HumArray2.0, UCSF Comprehensive Cancer Center Microarray Core) (Snijders et al., 2001) . We acquired 16-bit 1024 Â 1024 pixel DAPI, Cy3 and Cy5 images using a custom-built CCD camera system (Pinkel et al., 1998) and carried out image and data analysis using UCSF SPOT (Jain et al., 2002) . We used SPROC software to automatically filter the data to reject data points based on low DAPI intensity, low correlation between Cy3 and Cy5 within each segmented spot and low reference/DAPI signal intensity. We declared as missing observations with no replicates or with standard deviation of the replicates greater than 0.2. We screened out clones for the following reasons: data were missing in more than 15% of the samples, ratios on the clones had shown a median absolute value >0.2 in the normal samples, clones were not mapped on the genome sequence, or they were known as common copy number polymorphisms. For each tumor, we plotted the data in genome order as the mean log 2 ratio of the replicate spots for each clone normalized to the genome Table A) versus log 2 ratio observed on a BAC clone either containing or closest to each corresponding gene. We highlighted samples, which were more than twofold overexpressed relative to normal tissue in pink, samples downregulated more than twofold relative to normal tissue in light blue and samples in which expression of the gene was not detected in gray at the bottom of the plot. We observed that amplified genes (e.g. GLI2, JAG1, FJX1, RBPSUH) were always overexpressed when amplified, but more frequently genes were overexpressed without amplification (e.g. GLI2, GLI1, JAG1, FJX1, RBPSUH, DLL1, NOTCH4) median log 2 ratio. Array data are available in Supplementary  Table B .
Statistical analysis
To enumerate genomic aberrations in tumors, we estimated the experimental variability of each CGH profile (s.d.) by taking the median of the median absolute deviations of the measurements on clones with the same copy number in that profile (Fridlyand et al., 2004) . We declared a clone gained (lost) if its absolute value exceeded 2.5 times the s.d. for a given profile. We used the Fisher exact test to test for independence of TP53 mutation status with EGFR and CCND1 amplifications and with the cluster assignments. For these analyses, we identified high-level amplifications by considering the magnitude and the width of the peak (Fridlyand et al., 2004) . When comparing groups of tumors with or without TP53 mutation, we tested for differential copy number at each clone on the array using a t-statistic with pooled variance. To assess significance for individual clones, we obtained the maxTadjusted permutation-based P-values (Westfall and Young, 1993) . We declared a clone to have a significantly different copy number between the two groups if its adjusted P-value was less than 0.05. Thus, there is less than 5% chance of obtaining one false positive result or more.
Quantitative RT-PCR
We isolated RNA from consecutive sections of formalin-fixed paraffin-embedded tumor resection or biopsy specimens (Macabeo-Ong et al., 2003) and performed real-time quantitative RT-PCR as described previously (Neve et al., 2002) in the UCSF Comprehensive Cancer Center Genome Analysis Shared Resource Facility. We used ABI Assays-on-Demand Expression assays. The specific assays used for each gene are provided in Supplementary Table A Expression levels were determined relative to expression of GUSB in each sample. Gene expression levels in tumors were compared to the mean expression levels of three normal tissue samples. We observed little variation in expression among the normal samples (Supplementary Table A) . For most genes, twofold differences in expression in tumors relative to normals were greater than two s.d.'s above or below the mean of the expression in normals.
TP53 sequencing
We amplified exons 5-8 of TP53 from genomic DNA of 75 tumors (23 tongue, 16 buccal mucosa, 17 floor of mouth, 19 gingiva) and carried out cycle sequencing as described previously (Moore et al., 2000) using modified primer sequences for exons 7 (forward: 5 0 -TGCCAC AGGTCTCCCCA-3 0 and reverse: (5 0 -ATGGAAGAAAT CGGTAAGAGGTG-3 0 ) and 8 (forward: 5 0 -CCTTACTGC CTCTTGCTTC-3 0 and reverse: 5 0 -CATAACTGCACCCTT GGTC-3 0 ).
